Overview of clinical efficacy and safety of pharmacologic strategies for blood conser

Jan B. Wade · #1 (**permalink**) 11-20-2005, 08:18 AM

http://www.ncbi.nlm.nih.gov/entrez/q...191&query_hl=1

Am J Health Syst Pharm. 2005 Sep 15;62(18 Suppl 4):S15-9.

Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation.

Levy JH.

Emory University School of Medicine, 1364 Clifton Road NE, Atlanta, GA 30322, USA. jerrold_levy@emoryhealthcare.org

PURPOSE: The pharmacologic management of hemostasis in patients undergoing surgery with cardiopulmonary bypass is discussed. SUMMARY: Nearly 45 studies involving 7,000 patients have reported efficacy of aprotinin in blood conservation. Both in primary coronary artery bypass graft (CABG) surgeries and in repeat surgeries, aprotinin treatment significantly reduces the incidence of blood transfusions and the number of units of blood transfused. These effects have been observed for red blood cell, platelet, and other blood products. The safety of aprotinin treatment has been extensively evaluated in randomized clinical trials, in postmarketing databases, and in systematic reviews of the literature. Overall, data do not indicate that aprotinin treatment increases mortality, myocardial infarction, or renal failure. These findings are supported by the results of a recent meta-analysis of 35 studies in patients undergoing CABG surgery. In addition, the meta-analysis suggests that aprotinin treatment was associated with a reduced incidence of stroke and a trend toward a reduced incidence of atrial fibrillation. Although lysine analogs, desmopressin, and recombinant factor VIIa are sometimes used to reduce bleeding, only aprotinin is indicated for use during CABG surgery. CONCLUSION: The future of cardiac surgery will be marked by an increasingly complex, high-risk group of patients and a greater need for multiple pharmacologic options for reducing bleeding. Pharmacologic approaches that attenuate the activation of the hemostatic system and inflammation need to be employed to decrease coagulopathies and the need for allogeneic blood administration.

PMID: 16227191 [PubMed - in process]

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes	Rate This Thread
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode	Rate This Thread:

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
Blood conservation strategies in major orthopaedic surgery: efficacy, safety and ...	Sharon Grant	Medical Articles and Abstracts	0	12-29-2008 10:17 PM
Overview of Clinical Efficacy and Safety of Pharmacologic Strategies for Blood Conser	Sharon Grant	Medical Articles and Abstracts	0	11-20-2005 08:45 PM
Safety and efficacy of superselective angioembolization in control of lower gastroint	Nika	Medical Articles and Abstracts	0	04-01-2005 07:51 PM
The efficacy and safety of aprotinin for hemostasis during intracranial surgery	Jan B. Wade	Medical Articles and Abstracts	0	08-08-2003 10:35 AM
Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia	Jan B. Wade	Medical Articles and Abstracts	0	05-13-2003 09:59 AM

Overview of clinical efficacy and safety of pharmacologic strategies for blood conser

Welcome to the latest in bloodless medicine and blood transfusion alternatives.

We are a community of medical professionals and members of the public who are responding to the worldwide concern about the efficacy, cost and availability of donor blood.

Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)